dChan
Anonymous ID: f2564c Aug. 19, 2025, 5:08 p.m. No.23483010   🗄️.is 🔗kun

CDC Hit With Lawsuit Over Failure to Test Cumulative Effect of 72-Dose Childhood Vaccine Schedule

The CDC has never studied the combined effects and the accumulating dangers of administering all of the vaccines.

Aug 19, 2025

 

Two doctors who lost their medical licenses because they questioned the CDC’s vaccine recommendations for children are suing the agency for failing to test the cumulative effect of the 72-dose schedule on children’s health.

 

Drs. Paul Thomas and Kenneth P. Stoller and Stand for Health Freedom filed the lawsuit last week in federal court, alleging the lack of safety testing violates federal law and children’s constitutional rights.

 

The lawsuit names Susan Monarez, Ph.D., in her official capacity as director of the Centers for Disease Control and Prevention (CDC).

 

Attorney Rick Jaffe, who represents the plaintiffs, said the lawsuit “goes to the heart of the CDC’s childhood immunization program — a 72-plus dose medical intervention schedule that has never been tested.”

 

According to the complaint, the CDC’s childhood immunization schedule “is only based on an evaluation of short-term individual vaccine risks,” as the CDC “has never studied the combined effects and the accumulating dangers of administering all of the vaccines.”

 

more:

 

https://www.vigilantfox.com/p/cdc-hit-with-lawsuit-over-failure

Anonymous ID: f2564c Aug. 19, 2025, 5:11 p.m. No.23483018   🗄️.is 🔗kun   >>3155 >>3239 >>3421 >>3592 >>3604

New Study Links Fenbendazole to Remission or Near-Remission in Three Stage IV Cancer Patients

Fenbendazole is proving to be far more than a simple veterinary drug.

Aug 19, 2025

 

Fenbendazole (FBZ) is a low-cost veterinary antiparasitic drug that has gained global attention as a potential anticancer therapy. Like ivermectin—another antiparasitic widely repurposed in research and clinical practice for its potent anti-tumor effects—fenbendazole appears to work far beyond its original veterinary use.

 

Preclinical studies show fenbendazole disrupts cancer cell survival through multiple pathways, but until now, human evidence has been scarce.

 

A newly published case series by Dr. William Makis et al in Case Reports in Oncology presents three remarkable patients with advanced, stage IV cancers (breast, prostate, and melanoma) who self-administered Fenbendazole outside conventional oncology protocols. All three achieved either complete or near-complete remission — sustained for up to three years — without chemotherapy:

 

more:

https://www.vigilantfox.com/p/new-study-links-fenbendazole-to-remission